To validate the role of ADAM9 in prostate cancer progression, we stably downregulated ADAM9 expression in androgen-independent, bone metastatic PC3 prostate cancer cells and androgen-dependent LNCaP prostate cancer cells with either retroviral or lentiviral vectors carrying ADAM9-specific shRNA. Here, ADAM9 is linked to Familial prostate cancer.